Related Experiment Video
Updated: May 7, 2026
10:04
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.0K
A Single-Center Study on Frontline Treatment for Multiple Myeloma Patients With 1q Abnormalities
Ashish Patel1, Esther Masih-Khan1, Adam Smith2
1Department of Medical Oncology and Hematology University Health Network-Princess Margaret Cancer Centre Toronto ON Canada.
Ejhaem
|May 12, 2025
Summary
Chromosome 1q copy gains are common in multiple myeloma (MM). This genetic abnormality is linked to poorer outcomes and more advanced disease in MM patients.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Chromosome 1q copy gains (1q-gain) are frequently observed in multiple myeloma (MM).
- 1q gain is recognized as a significant prognostic factor associated with adverse clinical outcomes in MM patients.
Purpose of the Study:
- To investigate the clinical outcomes of newly diagnosed MM patients with and without 1q gain.
- To analyze the association between 1q gain and other cytogenetic abnormalities, disease stage, and treatment strategies.
Main Methods:
- Retrospective analysis of 275 newly diagnosed MM patients at Princess Margaret Cancer Centre.
- Comparison of clinical outcomes between patients with and without 1q gain.
- Assessment of International Staging System (ISS) stage and cytogenetic abnormalities.
Main Results:
- 161 out of 275 patients (58.5%) exhibited 1q gain.
- Patients with 1q gain were more likely to have high-risk cytogenetic abnormalities (34.8% vs. 14.0%) and advanced ISS stage (ISS III).
- A higher proportion of patients with 1q gain received tandem autologous stem cell transplant (ASCT) (36.2% vs. 8.7%).
Conclusions:
- 1q gain is associated with adverse prognostic features in MM.
- The presence of 1q gain impacts clinical outcomes and treatment patterns in MM patients.
- This single-center study underscores the clinical significance of 1q gain in multiple myeloma.
